On November 8, 2022 Emelie will take over the important role of CTO of Prostatype Genomics from Lidi Xu, who has held the position since 2019. Lidi is leaving the company to move back to China with her family but will continue to work on various projects for Prostatype Genomics. Emelie Berglund has a PhD in Biotechnology from the Royal Institute of Technology in Stockholm, and more than seven years of combined research experience within prostate cancer.

After her degree, Emelie has led the R&D operations of a Swedish life science company that develops products in cancer detection and biomarker analysis. Emelie's main tasks will be to strengthen the scientific footprint of Prostatype Genomics by initiating, running, and coordinating validation studies around the world, ensuring that the results are published in the right channels and working with product development of the Prostatype® Test System, the company's product for prognosticating the aggressiveness of a prostate cancer. Emelie's focus areas are in line with previously communicated objectives from Prostatype Genomics.

Emelie will also work in close collaboration with the commercial part of the company as there is great interest in Prostatype® in all priority markets. The company is currently in advanced discussions with leading urologists who have already used and evaluated Prostatype® and is on its way to a more routine use of the product. The increased use of Prostatype® has led to a significant influx of further contacts with customers, where Emelie's skills and experience will ensure that the company continue to deliver a continued good service also in terms of the scientific discussions.